P coronary intervention with stenting improves epicardial large vessel lumen diameters but can be detrimental to the microcirculation as a result of either downstream embolization or vasospasm. Coronary flow reserve (CFR) is a measurement of the capacity of blood flow that is augmented in response to adenosine (hyperemic flow) and is a valuable tool in assessing the integrity of the microvasculature after stent placement. We hypothesized that patients treated with eptifibatide in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial1 would have improved CFR after elective stent placement compared with patients receiving placebo. Furthermore, we hypothesized that tissue level perfusion would be improved with eptifibatide therapy, and we assessed the kinetics of myocardial perfusion using digital subtraction angiography. • • • The ESPRIT trial was a double-blind, multicenter, randomized, parallel group, placebo-controlled trial of planned, nonemergency stenting of native coronary arteries in 2,064 patients.1 Patients were allocated in a 1:1 ratio between eptifibatide and placebo immediately before planned percutaneous coronary stent implantation. Eptifibatide was administered as a 180 mg/kg bolus followed by a 2.0 mg/kg/min infusion for 18 to 24 hours, with a second 180 mg/kg bolus given 10 minutes after the first. An angiographic substudy was conducted at 3 sites that enrolled 65 patients to assess CFR and myocardial perfusion at the completion of the intervention. The Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (CTFC), the number of cine frames required for contrast to first reach standardized distal coronary landmarks in the culprit artery, was measured using a frame counter on a cine viewer.2,3 After stenting, patients received intracoronary adenosine (24 to 36 mg in the left anterior descending artery and left circumflex artery; 18 to 24 mg in the right coronary artery). The CTFC was assessed after stenting and 15 seconds after adenosine administration in the primary culprit lesion by the angiographic core laboratory, which was blinded to treatment assignment. CFR was calculated as the ratio of preadenosine CTFC divided by postadenosine CTFC, which has been validated in the literature as highly correlated with Doppler-derived CFR (r 5 0.88, p ,0.0001).4 To quantitate the kinetics of dye entry into the myocardium, digital subtraction angiography was used. Digital subtraction angiography was performed at end-diastole by aligning cine frame images before dye filled the myocardium with the frame in which dye first reached its peak brightness. The spine, ribs, diaphragm, and the epicardial artery were then subtracted. A representative region of the myocardium was sampled that was free of overlap by epicardial arterial branches to determine the increase in the grayscale brightness of the myocardium. The circumference of the myocardial blush was measured using a handheld planimeter (Fowler, Inc., Medford, Massachusetts). The frame count divided by the number of frames per second was used to measure the time elapsed during angiography to quantitate the rate of increase in the growth (centimeters per second) and brightness (gray per second) of myocardial blush. The digital subtraction angiographic reserve was calculated as the relative improvement in the rate of increase in brightness after adenosine: after adenosine (gray per second) divided by after stenting (gray per second). Blush was also assessed visually using the TIMI myocardial perfusion grade.5 The size (centimeters) and brightness of the myocardium (gray) were multiplied together to yield gray centimeters per second as a simultaneous index, integrating brightness and size of myocardial perfusion. Analyses were performed using Stata statistical software version 6.0.6 Variables were compared using the Fisher’s exact test or chi-square test for categorical data and the Student’s t test for continuous variables. Variables known to impact the CTFC (culprit location and reference diameter) and myocardial blush were adjusted for in multivariate models.5,7 There was no difference between patients who received placebo and those on eptifibatide with respect to baseline and postintervention angiographic characteristics (Table 1). CFR was greater among patients who received eptifibatide than patients on placebo (1.78 6 0.95, n 5 16 vs 1.28 6 0.40, n 5 27; p 5 From the Cardiovascular Division, Department of Medicine, the University of California San Francisco, San Francisco, California; The Beth Israel Deaconess Medical Center, Boston, Massachusetts; Sunnybrook Health Science Center, Toronto, Ontario, Canada; Jackson/ Madison County General Hospital, Jackson, Tennessee; COR Therapeutics, San Francisco, California; and Duke Clinical Research Institute, Durham, North Carolina. This study was supported in part by a grant from Cor Therapeutics, Inc., South San Francisco, California. Dr. Gibson’s address is: Chief of Interventional Cardiology, University of California San Francisco, 3333 California Street, Suite 430, San Francisco, California 94118. E-mail: mgibson@perfuse.org. Manuscript received October 25, 2000; revised manuscript received and accepted January 5, 2001.
Read full abstract